Basic research on molecular target therapy with radiotherapy for pancreatic cancer
Project/Area Number |
23791447
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Radiation science
|
Research Institution | Keio University |
Principal Investigator |
SEKI Satoshi 慶應義塾大学, 医学部, 助教 (30398614)
|
Project Period (FY) |
2011 – 2012
|
Project Status |
Completed (Fiscal Year 2012)
|
Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2012: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Fiscal Year 2011: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Keywords | 分子標的薬 / 放射線 / 放射線併用法 / 膵臓臓癌 / 膵癌 / 分子標的治療 / HER2 / VEGF |
Research Abstract |
The molecular target drug, anti-EGFR antibody, is already used for the HER2 expression breast cancer in clinical. An effect of this drug is expected in pancreatic cancer and is in a clinical trial. Although there was few reports to study it's affect of co
|
Report
(3 results)
Research Products
(1 results)